Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Subscribe To Our Newsletter & Stay Updated